1.1.1.205 IMP dehydrogenase blood plasma - 736152 1.1.1.21 aldose reductase blood plasma - 738005 1.1.99.1 choline dehydrogenase blood plasma choline and betaine levels 688563 1.11.1.9 glutathione peroxidase blood plasma - 696581, 700167 1.11.2.2 myeloperoxidase blood plasma - 712327, 764087, 764466 1.13.11.19 cysteamine dioxygenase blood plasma Cysteamine levels in plasma of rats fed the cysteamine supplemented diet are significantly higher than those in tissues of rats fed basal diet. Rats fed the cysteamine-supplemented diet have no markedly elevated levels of hypotaurine in plasma. 671185 1.13.11.34 arachidonate 5-lipoxygenase blood plasma - 711711 1.13.11.52 indoleamine 2,3-dioxygenase blood plasma - 712647 1.13.99.1 inositol oxygenase blood plasma from mice with acute kidney injury, MIOX expression is undetectable in healthy mice plasma -, 744739 1.13.99.1 inositol oxygenase blood plasma plasma MIOX is increased in critically ill patients with acute kidney injury compared with patients without acute kidney injury and is highest in patients with oliguric acute kidney injury 744739 1.14.13.39 nitric-oxide synthase (NADPH) blood plasma - 701194 1.14.14.18 heme oxygenase (biliverdin-producing) blood plasma - 735090 1.14.14.55 quinine 3-monooxygenase blood plasma - 744743 1.14.16.4 tryptophan 5-monooxygenase blood plasma - 744508 1.14.17.1 dopamine beta-monooxygenase blood plasma - 660336, 686516 1.14.17.1 dopamine beta-monooxygenase blood plasma a functional -1021C3T polymorphism in the DBH gene regulates plasma DBH activity, and individuals with the genotype T/T have genetically determined low DBH activity in their plasma 703268 1.14.17.1 dopamine beta-monooxygenase blood plasma dopamine beta-hydroxyase is reduced in rats subjected to chronic mild stress for 5 weeks. Imipramine treatment minimizes these chronic mild stress-induced reductions 675798 1.14.19.1 stearoyl-CoA 9-desaturase blood plasma - 696683 1.14.19.30 acyl-lipid (8-3)-desaturase blood plasma - 734621, 734622, 746199 1.16.3.1 ferroxidase blood plasma - -, 696112, 763223 1.17.3.2 xanthine oxidase blood plasma - 744744 1.17.3.2 xanthine oxidase blood plasma enzyme activity in plasma of northern elephant seals during prolonged fasting and rest and voluntary associated apneas 744744 1.17.3.2 xanthine oxidase blood plasma low activity 744744 1.4.3.21 primary-amine oxidase blood plasma - 391908, 391914, 391915, 391916, 391932, 686264, 686850, 687449, 688482, 688483, 724322 1.4.3.21 primary-amine oxidase blood plasma semicarbazide-sensitive amine oxidase overexpression in cerebrovascular tissue of patients with Alzheimer’s disease cerebral amyloid angiopathy correlates with high SSAO activity in plasma of severe Alzheimer’s disease patients 688490 1.4.3.22 diamine oxidase blood plasma - 391923 1.4.3.22 diamine oxidase blood plasma amitriptyline at 0.03, 0.05, 0.1 and 0.5 mM concentrations lower enzyme activity in the plasma of the heparinised rat by 14, 22, 23 and 28%, respectively 686558 1.4.3.22 diamine oxidase blood plasma determination of fresh plasma diamine oxidase activity may serve as an effective tool to diagnose Cu deficiency in the bovine 687323 1.4.3.22 diamine oxidase blood plasma in vitro treatment with 100 nM, 0.05, 0.1 and 0.5 mM amitriptyline increases the guinea pig plasma diamine oxidase activity by 5, 7, 17 and 11%, respectively 686558 1.4.3.22 diamine oxidase blood plasma mean/median concentrations are between 0.5 and 1.5 ng/ml in healthy volunteers (n=58) and mastocytosis patients (n=19) and plateau at approximately 145 ng/ml during pregnancy 764513 1.4.3.3 D-amino-acid oxidase blood plasma - 743131 1.5.1.20 methylenetetrahydrofolate reductase [NAD(P)H] blood plasma - 705297 1.6.3.5 renalase blood plasma - 741775, 742454 1.8.1.9 thioredoxin-disulfide reductase blood plasma - 742848 1.8.3.1 sulfite oxidase blood plasma - 691671 1.8.3.5 prenylcysteine oxidase blood plasma VLDL contains a greater protein content of PCL1 than LDL or HDL 706670 2.1.1.1 nicotinamide N-methyltransferase blood plasma - 690123 2.1.1.13 methionine synthase blood plasma - 705297 2.1.1.17 phosphatidylethanolamine N-methyltransferase blood plasma - 672830, 720359 2.1.1.2 guanidinoacetate N-methyltransferase blood plasma - 705297 2.1.1.2 guanidinoacetate N-methyltransferase blood plasma L197P mutation in exon 6: guanidinoacetate increases to 33.6 microMol/l, creatine decreases to 24 microMol/l 676024 2.1.1.5 betaine-homocysteine S-methyltransferase blood plasma - 705297 2.1.4.1 glycine amidinotransferase blood plasma - 673131, 705297 2.3.1.20 diacylglycerol O-acyltransferase blood plasma - 757321 2.3.1.43 phosphatidylcholine-sterol O-acyltransferase blood plasma - 685088, 686314, 686317, 686547, 686933, 687969, 688067, 702260, 702466, 703245, 703246, 703346, 703664, 703789, 705467, 705507, 705896, 706707, 718994, 720368, 737191, 756305, 756667, 757166, 757930 2.3.1.43 phosphatidylcholine-sterol O-acyltransferase blood plasma about 75% of plasma LCAT is associated with HDL 703346 2.3.1.43 phosphatidylcholine-sterol O-acyltransferase blood plasma activity of LCAT in men with cardiovascular disease, CVD, compared to healthy men, overview. Plasma LCAT activity is 5% higher in CVD cases in association with higher total cholesterol, non-HDL cholesterol and triglycerides, ge-adjusted incident CVD is increased with higher LCAT activity, overview 701993 2.3.1.43 phosphatidylcholine-sterol O-acyltransferase blood plasma LCAT levels are higher in females compared to males 705010 2.3.1.43 phosphatidylcholine-sterol O-acyltransferase blood plasma the enzyme circulates in plasma, predominantly in association with high-density lipoproteins 735428 2.3.1.6 choline O-acetyltransferase blood plasma - 737113 2.3.2.13 protein-glutamine gamma-glutamyltransferase blood plasma - 487858 2.3.2.13 protein-glutamine gamma-glutamyltransferase blood plasma coagulation factor XIIIa 487833 2.3.2.13 protein-glutamine gamma-glutamyltransferase blood plasma identical with enzyme from placenta or platelets 487820 2.3.2.2 gamma-glutamyltransferase blood plasma - 737142 2.3.2.2 gamma-glutamyltransferase blood plasma elevated GGT in diabetic children could be due to release from apoptotic cells 686578 2.3.2.2 gamma-glutamyltransferase blood plasma four GGT fractions of different molecular weight are detected in all subjects of both genders: b-GGT, m-GGT, s-GGT (likely lipoprotein-bound, molecular masses >2000, 940, and 140 kDa, respectively), and a free fraction (f-GGT, 70 kDa). Higher total GGT activity in males is related mainly to f-GGT 684407 2.3.2.2 gamma-glutamyltransferase blood plasma plasma layer stratification might occur in primary lithium-heparin tubes for a limited number of routine clinical chemistry tests, introducing a statistically significant bias in the measurement of gamma-glutamyltransferase, lactate dehydrogenase, triglycerides and C-reactive protein in the upper vs. the bottom section. When delayed testing is necessary for these parameters, plasma should be separated after centrifugation and appropriately mixed before delayed/repeated analysis or aliquoting 686156 2.4.1.152 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase blood plasma - 639518 2.4.1.152 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase blood plasma enzyme activity is significantly higher in patients with chronic liver diseases than in that of normal controls 639526 2.4.1.152 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase blood plasma in individuals with plasma fucosyltransferase deficiency from Indonesia, either a missense mutation, G739A, in the catalytic domain, or a nonsense mutation, C945A, truncating the COOH terminus of the enzyme, leads to the total loss of the enzymatic activity of FUT6. 9% of individuals on the island of Java lack the plasma type enzyme. Activity is elevated in patients with a variety of malignant disorders, including liver cancer, elevated in heavy alcohol drinkers. Reduction of enzyme level in patients with schizophrenia 639521 2.4.1.152 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase blood plasma the plasma enzyme appears at the last trimester of gestation 639532 2.4.1.165 N-acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase blood plasma group O 488678 2.4.1.344 type 2 galactoside alpha-(1,2)-fucosyltransferase blood plasma - 740517 2.4.1.37 fucosylgalactoside 3-alpha-galactosyltransferase blood plasma - 489126, 489129 2.4.1.40 glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase blood plasma - 489126 2.4.1.40 glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase blood plasma A 489162, 489163 2.4.1.40 glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase blood plasma blood group A1 489164 2.4.1.40 glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase blood plasma blood group A1 and A2 489126 2.4.1.68 glycoprotein 6-alpha-L-fucosyltransferase blood plasma - 699825 2.4.1.69 type 1 galactoside alpha-(1,2)-fucosyltransferase blood plasma - 740517 2.4.2.1 purine-nucleoside phosphorylase blood plasma - 735978, 736556 2.4.2.26 protein xylosyltransferase blood plasma - 703904 2.4.2.26 protein xylosyltransferase blood plasma XylT levels in plasma are approximately 200% lower than those in serum due in part to XylT released by platelets during blood clotting in vitro. In Xylt2+/+ mice, total serum XylT activity is 42% higher than in plasma. In Xylt2-/- mice, no significant difference between serum and plasma total XylT activity 703904 2.4.2.4 thymidine phosphorylase blood plasma - 685912 2.4.2.8 hypoxanthine phosphoribosyltransferase blood plasma - 759254 2.4.3.1 beta-galactoside alpha-(2,6)-sialyltransferase blood plasma - -, 701687, 703898 2.5.1.6 methionine adenosyltransferase blood plasma - 705297 2.6.1.1 aspartate transaminase blood plasma - 703947 2.6.1.2 alanine transaminase blood plasma - 760225 2.6.1.7 kynurenine-oxoglutarate transaminase blood plasma - 703233 2.6.1.7 kynurenine-oxoglutarate transaminase blood plasma KAT I activity is significantly lower in plasma of patients with Parkinson's disease when compared with normal individuals 675532 2.6.1.7 kynurenine-oxoglutarate transaminase blood plasma KAT II activity is significantly lower in plasma of patients with Parkinson's disease when compared with normal individuals 675532 2.7.1.165 glycerate 2-kinase blood plasma - 722379 2.7.1.171 protein-fructosamine 3-kinase blood plasma - 707456 2.7.1.21 thymidine kinase blood plasma - 758984 2.7.1.22 ribosylnicotinamide kinase blood plasma - 738213 2.7.1.30 glycerol kinase blood plasma Aqp7-/- knockout mice have significantly lower plasma glycerol level under 12 h fasting conditions. 682503 2.7.1.40 pyruvate kinase blood plasma - 661215 2.7.3.2 creatine kinase blood plasma - 642381 2.7.3.2 creatine kinase blood plasma creatine kinase activity is much greater females than in males. Plasma creatine kinase activity may reflect the protein turnover, which is closely related to muscle growth rate 687322 2.7.3.2 creatine kinase blood plasma the inter-individual variation in creatine kinase activity in the general population is wide, ranging from below 25 to up to 5000 IU/L5, with particularly high levels in men and in persons of African ancestry 739653 2.7.8.27 sphingomyelin synthase blood plasma - 707306, 738955, 760476 2.8.2.15 steroid sulfotransferase blood plasma - 661953 2.8.2.4 estrone sulfotransferase blood plasma - 739665 3.1.1.1 carboxylesterase blood plasma - 710690, 751792 3.1.1.2 arylesterase blood plasma - 665028, 678376, 678464, 681730, 691230, 691855, 693321, 693517, 695193, 714002, 714637 3.1.1.25 1,4-lactonase blood plasma - 691230, 94285, 94286 3.1.1.3 triacylglycerol lipase blood plasma - 693511, 694786 3.1.1.3 triacylglycerol lipase blood plasma post-heparin 80840 3.1.1.3 triacylglycerol lipase blood plasma post-heparin plasma 665123